Compare OHI & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OHI | NBIX |
|---|---|---|
| Founded | N/A | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 15.5B |
| IPO Year | 2001 | 1996 |
| Metric | OHI | NBIX |
|---|---|---|
| Price | $45.66 | $135.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 29 |
| Target Price | $51.44 | ★ $206.81 |
| AVG Volume (30 Days) | ★ 1.9M | 1.3M |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | ★ 5.97% | N/A |
| EPS Growth | 25.16 | ★ 41.95 |
| EPS | 1.66 | ★ 3.30 |
| Revenue | ★ $1,190,099,000.00 | $161,626,000.00 |
| Revenue This Year | N/A | $36.39 |
| Revenue Next Year | $6.48 | $16.93 |
| P/E Ratio | ★ $27.42 | $41.55 |
| Revenue Growth | 13.19 | ★ 977.51 |
| 52 Week Low | $39.26 | $122.14 |
| 52 Week High | $52.39 | $186.12 |
| Indicator | OHI | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 49.81 | 34.85 |
| Support Level | $45.17 | $125.18 |
| Resistance Level | $46.90 | $138.74 |
| Average True Range (ATR) | 0.81 | 3.55 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 66.96 | 26.05 |
Omega Healthcare Investors Inc is a real estate investment trust that invests in healthcare-related real estate properties located in the United States (U.S.), the United Kingdom (U.K.), and Canada. The company's objective is to provide attractive returns to investors while serving as the preferred capital partner to its third-party healthcare operating companies and affiliates, as well as other third-party healthcare operators, allowing them to focus on delivering a high level of care to their resident patients. Omega's investment portfolio mainly consists of skilled nursing facilities, assisted living facilities (ALFs), including care homes in the U.K., independent living facilities, rehabilitation and acute care facilities, and continuing care retirement communities.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.